English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Patients with advanced malignant disease show an apparent lesser degree of lymphocyte sensitization to cancer antigen when tested under standard conditions than do early cases. In the serum of cancer patients there is a lymphocyte response depressing factor whose titre rises as the neoplasm becomes more extensive. The low lymphocyte response shown by advanced cancers is not, however, directly referable to this rise in depressive factor, but to removal by the tumour mass of specifically sensitized lymphocytes so that amongst the standard number of cells under routine test an adequate number does not remain to give a full response. Increasing the number of cells under test restores the result to the level found in moderately sized cancers. The "absorptive capacity" of large tumours for circulating sensitized lymphocytes is greater than can be provided by natural immunization produced by the tumour. Active immunization with a tumour antigen can be expected therefore to increase lymphocyte-associated defence against cancer.

Lymphocyte Sensitization in Advanced Malignant Disease: A Study of Serum Lymphocyte Depressive Factor